Sugi Predict

Sugi Predict / Targets / APOBEC3A

APOBEC3A

DNA dC->dU-editing enzyme APOBEC-3A · P31941 · APOBEC3A on Sugi Atlas →

49,705 patent compounds predicted against APOBEC3A, 31,117 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL170289 SCHEMBL170289 0.40 6/20
SCHEMBL67836 SCHEMBL67836 0.50 4/20
Pentolinium Pentolinium (SCHEMBL309648) 0.50 4/20
Pentolinium Pentolinium (SCHEMBL309647) 0.46 4/20
SCHEMBL14751 SCHEMBL14751 0.84 3/20
Iodide Iodide (SCHEMBL285057) 0.70 3/20
Iodide Iodide (SCHEMBL285058) 0.70 3/20
Bromide Bromide (SCHEMBL338369) 0.67 3/20
Bromide Bromide (SCHEMBL338370) 0.67 3/20
SCHEMBL329509 SCHEMBL329509 0.56 3/20
Trigonelline Trigonelline (SCHEMBL195666) 0.53 3/20
SCHEMBL372822 SCHEMBL372822 0.43 3/20
SCHEMBL366573 SCHEMBL366573 0.42 3/20
SCHEMBL319738 SCHEMBL319738 0.41 3/20
SCHEMBL372404 SCHEMBL372404 0.37 3/20
SCHEMBL232469 SCHEMBL232469 0.66 2/20
SCHEMBL160108 SCHEMBL160108 0.58 2/20
SCHEMBL64694 SCHEMBL64694 0.58 2/20
SCHEMBL140214 SCHEMBL140214 0.57 2/20
SCHEMBL140215 SCHEMBL140215 0.57 2/20

Clinical trials — most relevant to APOBEC3A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS PHASE4COMPLETED
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
Efficacy of Adaptogens in Patients With Long COVID-19 PHASE2/PHASE3COMPLETED
Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation PHASE2ACTIVE_NOT_RECRUITING
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer PHASE2ACTIVE_NOT_RECRUITING
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer PHASE2RECRUITING
Phase II ABT-888 With Cyclophosphamide PHASE2COMPLETED
Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia PHASE1/PHASE2ACTIVE_NOT_RECRUITING
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency PHASE1/PHASE2RECRUITING
Surgical Pembro +/- Olaparib w TMZ for rGBM PHASE2RECRUITING
Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency PHASE1COMPLETED
Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy PHASE1COMPLETED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma PHASE1RECRUITING
Role of Viral Reservoir, Immune Activation and Depletion in Persistent Viremia Persistent Viremia in People Living With HIV on Antiretroviral Therapy nanNOT_YET_RECRUITING
Evaluation of Adenosine Deaminase (ADA) Enzyme Deficiency in Patients With Lymphopenia and/or Elevated Immunoglobulin E nanUNKNOWN
Investigation of ADA Enzyme Deficiency nanUNKNOWN
Observational Study Evaluating the Prevalence of Enzyme Deficiency in Pulmonology Clinics (ADA) nanUNKNOWN
Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Proteinosis nanUNKNOWN
ADAR1 Expression Level in Rectal Cancer nanRECRUITING
Natural History of Autosomal Dominant Hearing Loss nanRECRUITING
Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA) nanRECRUITING
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
Characterisation of the Immune Response to SARS-CoV-2 Infection / COVID-19 in Type 1 Diabetes nanCOMPLETED
COsegregation of VARiants in Panel of Genes nanRECRUITING
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study nanRECRUITING
Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological Suppression nanCOMPLETED
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a APOBEC3A binder may also engage these)

ProteinNameSimilarity
Q694B8 — 0.988 Q694B8 →
Q694B9 — 0.987 Q694B9 →
Q1WBT4 — 0.987 Q1WBT4 →
Q7YR23 — 0.985 Q7YR23 →
Q694B7 — 0.985 Q694B7 →
Q7YR25 — 0.985 Q7YR25 →
Q694C1 — 0.984 Q694C1 →
APOBEC3G DNA dC->dU-editing enzyme APOBEC-3G 0.984 landscape →
Q694B6 — 0.984 Q694B6 →
Q2PT36 — 0.984 Q2PT36 →
Q7YR24 — 0.983 Q7YR24 →
P60705 — 0.983 P60705 →
Q9GZX7 — 0.983 Q9GZX7 →
Q694C5 — 0.982 Q694C5 →
Q694C2 — 0.982 Q694C2 →
Q694C4 — 0.982 Q694C4 →
APOBEC3B DNA dC->dU-editing enzyme APOBEC-3B 0.982 landscape →
Q6NTF7 — 0.981 Q6NTF7 →
Q9WVE0 — 0.980 Q9WVE0 →
Q75W64 — 0.980 Q75W64 →
Q694C0 — 0.980 Q694C0 →
Q19Q52 — 0.979 Q19Q52 →
Q4VDN5 — 0.978 Q4VDN5 →
Q99J72 — 0.976 Q99J72 →
Q96AK3 — 0.975 Q96AK3 →
P60704 — 0.974 P60704 →
Q8IUX4 — 0.973 Q8IUX4 →
A9QA56 — 0.973 A9QA56 →
Q694B5 — 0.970 Q694B5 →
APOBEC3C DNA dC->dU-editing enzyme APOBEC-3C 0.968 landscape →